PLoS ONE (Jan 2020)

Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis.

  • Kazumichi Abe,
  • Hiroto Wakabayashi,
  • Haruo Nakayama,
  • Tomohiro Suzuki,
  • Masahito Kuroda,
  • Naoe Yoshida,
  • Jun Tojo,
  • Atsuko Kogure,
  • Tsuyoshi Rai,
  • Hironobu Saito,
  • Shinji Mukai,
  • Masashi Fujita,
  • Manabu Hayashi,
  • Atsushi Takahashi,
  • Hiromasa Ohira

DOI
https://doi.org/10.1371/journal.pone.0243473
Journal volume & issue
Vol. 15, no. 12
p. e0243473

Abstract

Read online

The present study aimed to investigate the incidence of hepatocellular carcinoma (HCC) and factors related to HCC occurrence after direct-acting antiviral (DAA) treatment in the Fukushima Liver Academic Group (FLAG). We conducted a multicenter retrospective cohort study of 1068 patients without cirrhosis (NC) or with compensated liver cirrhosis (LC) who achieved a sustained virologic response (SVR). First, we compared the cumulative HCC incidence and survival rates in NC (n = 880) and LC (n = 188) patients without a history of HCC treatment. Second, we performed multivariate analysis of factors related to HCC occurrence after DAA treatment. Overall, the average age was 65 years, and the male/female ratio was 511/557. Thirty-nine (4%) patients developed HCC. The cumulative 4-year HCC incidence and survival rates were 3.0% and 99.8% in NC patients and 11.5% and 98.5% in LC patients, respectively. The independent factors affecting HCC occurrence identified by multivariate analysis were the serum albumin (ALB) level before SVR for NC patients and the ALBI score, platelet count, and diabetes before SVR for LC patients. The factors related to HCC occurrence differed between NC and LC patients. Careful surveillance of post-SVR patients with these risk factors is needed.